India, Jan. 8 -- Two widely available drugs typically used to treat rheumatoid arthritis - tocilizumab and sarilumab - reduce the risk of death from Covid-19 by 24% and reduce stay in the intensive care unit by up to 10 days, results from a UK government-backed trial published on Thursday show.

Most of the data came from the REMAP-CAP trial when the drugs were administered in addition to a corticosteroid, such as dexamethasone, which was discovered in June 2020 through the RECOVERY clinical trial, which is already provided as standard of care to patients in the National Health Service (NHS).

The Department of Health said patients receiving these drugs left intensive care between seven and 10 days earlier on average. Updated guidance on ...